\BOOKMARK [1][-]{section.1}{Introduction}{}% 1
\BOOKMARK [1][-]{section.2}{Methods}{}% 2
\BOOKMARK [2][-]{subsection.2.1}{Dataset}{section.2}% 3
\BOOKMARK [2][-]{subsection.2.2}{Variant\040Class\040Observation\040Probability}{section.2}% 4
\BOOKMARK [2][-]{subsection.2.3}{Validation\040of\040Autosomal\040Dominant\040Estimates\040Using\040NFKB1}{section.2}% 5
\BOOKMARK [2][-]{subsection.2.4}{Validation\040Study\040for\040Autosomal\040Recessive\040CF\040Using\040CFTR}{section.2}% 6
\BOOKMARK [2][-]{subsection.2.5}{Validation of SCID-specific Estimates Using PID–SCID Genes}{section.2}% 7
\BOOKMARK [2][-]{subsection.2.6}{Protein\040Network\040and\040Genetic\040Constraint\040Interpretation}{section.2}% 8
\BOOKMARK [2][-]{subsection.2.7}{Gene\040Set\040Enrichment\040Test}{section.2}% 9
\BOOKMARK [2][-]{subsection.2.8}{Deriving\040novel\040PID\040classifications\040by\040genetic\040PPI\040and\040clinical\040features}{section.2}% 10
\BOOKMARK [2][-]{subsection.2.9}{Probability\040of\040observing\040AlphaMissense\040pathogenicity}{section.2}% 11
\BOOKMARK [1][-]{section.3}{Results}{}% 12
\BOOKMARK [2][-]{subsection.3.1}{Observation\040Probability\040Across\040Disease\040Genes}{section.3}% 13
\BOOKMARK [2][-]{subsection.3.2}{Validation\040studies}{section.3}% 14
\BOOKMARK [2][-]{subsection.3.3}{Genetic\040constraint\040in\040high-impact\040protein\040networks}{section.3}% 15
\BOOKMARK [2][-]{subsection.3.4}{New\040Insight\040from\040Functional\040Enrichment}{section.3}% 16
\BOOKMARK [2][-]{subsection.3.5}{Genome-wide\040Gene\040Distribution\040and\040Locus-specific\040Variant\040Occurrence}{section.3}% 17
\BOOKMARK [2][-]{subsection.3.6}{Novel\040PID\040classifications\040derived\040from\040genetic\040PPI\040and\040clinical\040features}{section.3}% 18
\BOOKMARK [2][-]{subsection.3.7}{Novel\040PID\040classifications\040derived\040from\040genetic\040PPI\040and\040clinical\040features}{section.3}% 19
\BOOKMARK [2][-]{subsection.3.8}{Probability\040of\040observing\040AlphaMissense\040pathogenicity}{section.3}% 20
\BOOKMARK [1][-]{section.4}{Discussion}{}% 21
\BOOKMARK [1][-]{section.5}{Conclusion}{}% 22
\BOOKMARK [1][-]{section.6}{Supplemental}{}% 23
\BOOKMARK [2][-]{subsection.6.1}{Validation\040studies}{section.6}% 24
\BOOKMARK [2][-]{subsection.6.2}{Hierarchical\040Clustering\040of\040Enrichment\040Scores\040for\040Major\040Disease\040Categories}{section.6}% 25
\BOOKMARK [2][-]{subsection.6.3}{Interpretation\040of\040ClinVar\040Variant\040Observations}{section.6}% 26
\BOOKMARK [2][-]{subsection.6.4}{Novel\040PID\040classifications}{section.6}% 27
\BOOKMARK [2][-]{subsection.6.5}{Probability\040of\040observing\040AlphaMissense\040pathogenicity}{section.6}% 28
\BOOKMARK [1][-]{section.7}{Clinical\040Genetics\040Application}{}% 29
\BOOKMARK [2][-]{subsection.7.1}{Methods}{section.7}% 30
\BOOKMARK [2][-]{subsection.7.2}{Results}{section.7}% 31
\BOOKMARK [2][-]{subsection.7.3}{New\040version}{section.7}% 32
\BOOKMARK [1][-]{section.8}{Bayesian assessment of per‑patient variant risk}{}% 33
\BOOKMARK [2][-]{subsection.8.1}{Data\040preprocessing}{section.8}% 34
\BOOKMARK [2][-]{subsection.8.2}{Pathogenicity\040scoring}{section.8}% 35
\BOOKMARK [2][-]{subsection.8.3}{Posterior\040simulation}{section.8}% 36
\BOOKMARK [2][-]{subsection.8.4}{Present\040versus\040missing\040contribution}{section.8}% 37
\BOOKMARK [1][-]{section.9}{Results\040for\040the\040NFKB1\040proband}{}% 38
